These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 29395866)
1. New cancer blood test developed. Burki TK Lancet Oncol; 2018 Mar; 19(3):e140. PubMed ID: 29395866 [No Abstract] [Full Text] [Related]
2. Beyond Standard Practice in Liquid Biopsy: Selective Venous Sampling. Damascelli B; Tichà V; Repetti E; Dorji T J Vasc Interv Radiol; 2021 May; 32(5):668-671. PubMed ID: 33621662 [TBL] [Abstract][Full Text] [Related]
3. The role of cell-free DNA in predicting colorectal cancer prognosis. Cao B; Zhou X; Yang W; Ma J; Zhou W; Fan D; Hong L Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):39-48. PubMed ID: 28838275 [TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA Sun X; Li H; Sun M; Yuan Y; Sun L Future Oncol; 2019 Oct; 15(30):3513-3525. PubMed ID: 31578881 [No Abstract] [Full Text] [Related]
5. A Step Closer to Cancer Screening by Blood Test. Thierry AR Clin Chem; 2018 Oct; 64(10):1420-1422. PubMed ID: 29903875 [No Abstract] [Full Text] [Related]
6. Circulating Cell-Free DNA and Cancer Therapy Monitoring: Methods and Potential. Gahan PB Methods Mol Biol; 2019; 1909():31-46. PubMed ID: 30580421 [TBL] [Abstract][Full Text] [Related]
7. Clinical testing should be individualized, not based on populations. Walt DR J Clin Invest; 2019 Sep; 129(9):3472-3473. PubMed ID: 31478913 [No Abstract] [Full Text] [Related]
8. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Cheng F; Su L; Qian C Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063 [TBL] [Abstract][Full Text] [Related]
9. Grail to pour $1 billion into blood test to detect early cancer. Sheridan C Nat Biotechnol; 2017 Feb; 35(2):101-102. PubMed ID: 28178244 [No Abstract] [Full Text] [Related]
10. Liquid Biopsy: Emergence of an Alternative Cancer Detection Method. Law EW; Settell ML; Kurani SS; Eckert EC; Liu MC; Greenberg-Worisek AJ Clin Transl Sci; 2020 Sep; 13(5):845-847. PubMed ID: 32233063 [No Abstract] [Full Text] [Related]
11. Circulating Tumour Cells in Predictive Molecular Pathology: Focus on Drug-Sensitive Assays and 3D Culture. Pallante P; Pisapia P; Bellevicine C; Malapelle U; Troncone G Acta Cytol; 2019; 63(3):171-181. PubMed ID: 30759433 [TBL] [Abstract][Full Text] [Related]
12. Circulating-tumor DNA as an early detection and diagnostic tool. Butler TM; Spellman PT; Gray J Curr Opin Genet Dev; 2017 Feb; 42():14-21. PubMed ID: 28126649 [TBL] [Abstract][Full Text] [Related]
14. Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis. Ye M; Huang T; Ying Y; Li J; Yang P; Ni C; Zhou C; Chen S Oncotarget; 2017 Feb; 8(6):9230-9242. PubMed ID: 27999208 [TBL] [Abstract][Full Text] [Related]
15. Clinical utility versus futility: a tipping point for liquid biopsies in bladder cancer. Kouba E; Cheng L Future Oncol; 2019 Nov; 15(33):3751-3753. PubMed ID: 31651200 [No Abstract] [Full Text] [Related]
20. Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis. Routman DM; Chera BS; Gupta GP Cancer J; 2020; 26(2):116-123. PubMed ID: 32205535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]